Equities

Matinas BioPharma Holdings Inc

Matinas BioPharma Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.69
  • Today's Change-0.08 / -2.12%
  • Shares traded11.62k
  • 1 Year change-45.97%
  • Beta1.6587
Data delayed at least 15 minutes, as of Sep 21 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology (LNC Platform). Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options. It is expanding the utilization of the LNC Platform with small molecules and small oligonucleotides outside of infectious disease, targeting inflammation and oncology. It is also investigating a variety of LNC formulations of two small oligonucleotides designed to target inflammatory cytokines IL-17A and TNFα.

  • Revenue in USD (TTM)0.00
  • Net income in USD-22.91m
  • Incorporated2013
  • Employees32.00
  • Location
    Matinas BioPharma Holdings IncSuite 302, 1545 Route 206 SouthBEDMINSTER 07921United StatesUSA
  • Phone+1 (908) 443-1860
  • Fax+1 (302) 636-5454
  • Websitehttps://www.matinasbiopharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
NRX Pharmaceuticals Inc0.00-24.83m17.52m2.00---------1.62-1.620.00-1.700.00-------197.97-120.57---168.40-----------189.12--------24.14------
OpGen Inc1.96m-22.39m17.55m100.00------8.93-20.01-20.011.66-8.650.1553--6.09---176.99-87.95-15,455.17-127.653.1515.42-1,139.66-794.78---20.25----31.113.0212.38--40.20--
Spruce Biosciences Inc9.57m-43.11m18.17m22.00--0.3071--1.90-1.05-1.050.23381.430.095----330,069.00-42.79-41.24-52.43-46.49-----450.38-1,774.39---117.260.0412-------3.77------
Biomx Inc0.00-26.25m18.25m58.00---------0.4575-0.45750.000.39290.00----0.00-47.79---57.76--------------0.00------7.59------
Finch Therapeutics Group Inc0.00-14.17m18.31m18.00--1.29-----8.82-8.820.008.860.00-------25.20---28.80--------------0.00---87.57--34.80------
Lyra Therapeutics Inc1.82m-101.39m18.46m87.00--0.5959--10.14-1.61-1.610.02940.47330.0165----20,681.82-92.07-58.01-108.51-68.69-----5,570.88-6,235.31----0.00--14.314.60-13.39--95.14--
Matinas BioPharma Holdings Inc0.00-22.91m18.51m32.00--0.969-----5.10-5.100.003.810.00----0.00-78.48-44.62-85.80-48.25-------2,344.60----0.001---65.6255.71-9.26---16.46--
NanoViricides Inc0.00-9.51m18.55m7.00--1.74-----0.8115-0.81150.000.90170.00----0.00-63.30-43.54-65.85-46.29------------0.00-------5.94---8.90--
Cocrystal Pharma Inc0.00-17.93m18.72m12.00--1.08-----1.76-1.760.001.710.00----0.00-61.98-50.94-66.88-52.77-------1,501.78----0.00------53.69--33.34--
Bullfrog AI Holdings, Inc.65.00k-6.08m18.92m4.00--3.51--291.07-0.8441-0.84410.0090.68600.0107----16,250.00-100.10---117.94--92.00---9,331.34-----328.510.0596--550.00---91.11------
Brainstorm Cell Therapeutics Inc0.00-12.75m19.36m29.00---------0.2242-0.22420.00-0.04430.00----0.00-223.03-117.19---231.65--------------------29.18---45.34--
Synlogic Inc3.17m-56.16m19.65m6.00--1.23--6.20-7.24-7.240.35491.370.0628----528,333.30-111.31-40.57-131.17-43.82-----1,771.74-3,245.93----0.00--185.685.9913.40---48.05--
Minerva Neurosciences Inc0.00-33.65m19.72m9.00---------4.44-4.440.00-6.360.00----0.00-59.32-49.89-62.70-52.39-------442.65------------6.55------
Goldenwell Biotech Inc940.00-137.11k19.80m----5,169.71--21,063.83-0.0014-0.00140.000010.000040.00480.0031-----69.82---70.29--42.55---14,586.17--21.43--0.00---95.10--88.13------
MEI Pharma Inc66.75m26.16m19.86m46.000.75920.38910.7490.29743.933.9310.027.660.6498--29.151,451,174.0025.46-25.3130.38-28.59----39.18-122.05----0.00--19.9597.5641.53------
Data as of Sep 21 2024. Currency figures normalised to Matinas BioPharma Holdings Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.